Telmisartan, ramipril, or both in patients at high risk for vascular events by ONTARGET Investigators, Yusuf Salim, Teo Koon K, Pogue Janice, Dyal Leanne, Copland Ingrid, Schumacher Helmut, Dagenais Gilles, Sleight Peter, Anderson Craig in The New England journal of medicine (2008).

[PMID: 18378520] PubMed


In patients who have vascular disease or high-risk diabetes without heart failure, angiotensin-converting-enzyme (ACE) inhibitors reduce mortality and morbidity from cardiovascular causes, but the role of angiotensin-receptor blockers (ARBs) in such patients is unknown. We compared the ACE inhibitor ramipril, the ARB telmisartan, and the combination of the two drugs in patients with vascular disease or high-risk diabetes.

[ hide abstract ]

Discussed In Paper


Rx Annotations

No dosing information annotated.